Clinical outcomes associated with a digital standardized skin care regimen in acne-rosacea comorbidity: A real-world longitudinal study with cross-lagged and mediation analyses
Journal of the American Academy of Dermatology · 2026-07
DOI: 10.1016/j.jaad.2026.06.090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Yuxin Qing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Rosacea, Acne Vulgaris, Skin Care. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Xian Jiaotong University.
Abstract (Originalsprache)
BACKGROUND: Co-occurring acne and rosacea is challenging. A digital standardized skin care regimen (SSCG) may be associated with better real-world outcomes, but the clinical-barrier temporal sequence remains unclear. OBJECTIVE: To evaluate associations between SSCG participation and outcomes, the clinical-barrier temporal sequence, transepidermal water loss (TEWL) mediation, and communication frequency. METHODS: Single-center retrospective cohort with verified dual diagnosis. All patients received doxycycline plus azelaic acid; propensity score matching yielded 282 pairs. Primary outcome was IGA 0/1 at week 12. Cross-lagged, mediation, and E-value analyses were used. RESULTS: SSCG participation was associated with higher IGA 0/1 (54.6% vs 34.4%; RR = 1.59, 95%CI:1.31-1.92), lower relapse (18.8% vs 34.0%), and greater DLQI MCID attainment (91.1% vs 71.3%). Week-6 IGA predicted week-12 TEWL reduction; the reverse path was nonsignificant. TEWL mediated 12.4% of the estimated association. Communication frequency showed no dose-response. LIMITATIONS: Retrospective design, bundled intervention, possible self-selection and cost-related bias, chart-based adherence assessment, and unrecorded exposome and contraceptive changes. CONCLUSIONS: In this cohort, SSCG participation was associated with higher clearance and lower relapse. Findings are associative and hypothesis-generating.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.
- Department of Clinical Medicine, Xi'an Jiaotong University Medical School, Xi'an, China.
- Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shi'yan, China.
- Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Nursing, Xi'an Jiaotong University Medical School, Xi'an, China.
Förderung
- Xian Jiaotong University
Zitieren
APA
Qing, Y., Zhang, K., Xu, B., Wang, Y., Xiao, T., Yang, P., Yang, Y., Yu, B., Sun, H., Wu, N., Zhang, T., & Wu, J. (2026). Clinical outcomes associated with a digital standardized skin care regimen in acne-rosacea comorbidity: A real-world longitudinal study with cross-lagged and mediation analyses. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.06.090
Vancouver
Qing Y, Zhang K, Xu B, Wang Y, Xiao T, Yang P, et al. Clinical outcomes associated with a digital standardized skin care regimen in acne-rosacea comorbidity: A real-world longitudinal study with cross-lagged and mediation analyses. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.06.090
BibTeX
@article{Qing2026,
author = {Qing, Yuxin and Zhang, Kaijing and Xu, Bingyang and Wang, Yuanqin and Xiao, Tong and Yang, Peiwen and Yang, Yan and Yu, Biao and Sun, Hong and Wu, Na and Zhang, Tianxiao and Wu, Jiawen},
title = {Clinical outcomes associated with a digital standardized skin care regimen in acne-rosacea comorbidity: A real-world longitudinal study with cross-lagged and mediation analyses},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.06.090}
}
EUVIMED